Value
10.0/10data confidence 20%| Component | Sub-score |
|---|---|
| EV/EBITDA | 10.0 |
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Avalo is a pre-revenue, cash-burning biotech with single-program and single-supplier concentration, a confirmed downtrend and insider selling; its only support is a large but lightly covered analyst upside.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
Value depends on one pipeline asset, abdakibart (AVTX-009), manufactured by a single CDMO, with 3 HIGH concentration risks flagged. Risk breakdown | Pipeline progress or supplier diversification reduces the HIGH concentration risks flagged. | →Stable |
| CounterA setback in abdakibart or at the single manufacturer would hit the whole company with no other program to cushion it. | ||
Analysts see 415% upside, but coverage is light and the raw $34.80 target was rejected as implausible against a $6.76 price. Sentiment breakdown | Price holds above support near $6.33 as pipeline milestones are reached and coverage broadens. | →Stable |
| CounterThe 5.1x gap between the raw target and price was rejected as implausible, so the upside signal may not be reliable. | ||
The company is cash-burning with free cash flow at -32849% of revenue and revenue at zero in each of the last three quarters. Quality breakdown | Revenue becomes meaningful and cash burn narrows over the next 12 months. | →Stable |
| CounterWithout revenue, funding needs may force dilutive raises that hurt shareholders even if the science works. | ||
Momentum is 3.4 (below the engine's 4.5 threshold) with a death cross, falling on-balance volume and a 200-day average sloping down 7.1% over 30 days. Momentum breakdown | Momentum recovers above 4.5 as the stock stabilizes after a 72% drawdown. | ↑Improving |
| CounterThe MACD is already improving and RSI is 44, so the downtrend may be close to exhaustion. | ||
Insiders are net sellers, with 3 sales worth $395,474 in 90 days and no buys, a bearish signal. Insider | Insider selling stops and buying appears over the next 12 months. | →Stable |
| CounterThe sales are only 0.101% of market cap, which is minor and may reflect routine compensation-related selling. | ||
CounterA setback in abdakibart or at the single manufacturer would hit the whole company with no other program to cushion it.
CounterThe 5.1x gap between the raw target and price was rejected as implausible, so the upside signal may not be reliable.
CounterWithout revenue, funding needs may force dilutive raises that hurt shareholders even if the science works.
CounterThe MACD is already improving and RSI is 44, so the downtrend may be close to exhaustion.
CounterThe sales are only 0.101% of market cap, which is minor and may reflect routine compensation-related selling.
| Component | Sub-score |
|---|---|
| EV/EBITDA | 10.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.7 |
| Component | Sub-score |
|---|---|
| Analyst rating | 8.2 |
| Price target | 10.0 |
| erm sentiment | 4.1 |
| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 9.9 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 4.8 |
| growth rank | 5.0 |
| Component | Sub-score |
|---|---|
| bollinger | 7.3 |
| support resistance | 8.9 |
| 52w position | 0.0 |
| gap | 6.0 |
| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 7.3 |
| volatility | 0.0 |
| put call | 9.6 |
| implied vol | 0.0 |
| beta | 8.5 |
| debt equity | 10.0 |
| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
Market cap $391M below $400M minimum. Not in investable universe.
L1:HARD_BLOCK:MARKET_CAPSetupRecovery — Death cross but MACD improving, RSI 44
EdgeInst Constrain — Small cap ($0.4B) below institutional reach
SuitabilitySpeculative — Drawdown -72% (>40% off 52w high), Binary industry: Biotechnology
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 3.4<4.5 outcome against Value at 10.0 and asymmetric R:R of 0.00.
The strongest dimensions are Value at 10.0, Sentiment at 7.7, and Peer rank at 6.2; the weakest are Quality at 1.8, Momentum at 3.4, and Growth at 5.0. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifStock price falls below $5.00 from the current $6.76.
Trip ifHIGH concentration risk count falls below 2 from the current 3.
Trip ifQuarterly revenue exceeds $5M from the current $0.
Trip ifMomentum score rises above 5.0 from the current 3.4.
Trip ifTotal insider buy value over 90 days exceeds $100,000.